Pfizer (PFE)
(Delayed Data from NYSE)
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.09 USD
+0.12 (0.41%)
Updated Sep 27, 2024 04:02 PM ET
After-Market: $29.09 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Buy Pharma Giant AbbVie Stock Before Q4 Earnings for Dividend and Value?
by Benjamin Rains
Let's check out AbbVie to see if investors might want to buy the stock ahead of its fourth quarter fiscal 2020 financial release that's due out before the opening bell on Wednesday, Feb. 3...
Earnings Strength and Market Weakness
by Sheraz Mian
Market volatility notwithstanding, we have to acknowledge that the fundamental backdrop, as reflected in the outlook for earnings and interest rates, remains very favorable...
Pfizer's (PFE) Key Brands Likely to Drive Its Q4 Earnings
by Zacks Equity Research
Pfizer's (PFE) Biopharma unit becomes the "New Pfizer" following the separation of the Upjohn unit. The Q4 announcement will the first quarterly result for the "New Pfizer".
Personal Income Increased in December
by Zacks Equity Research
Personal Income Increased in December
Novavax's (NVAX) COVID-19 Vaccine 89.3% Effective in U.K. Study
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves its vaccine efficacy of 89.3% in late-stage study in the United Kingdom. Stock rises in after-hours trading.
Economic Prints, Q4 Reports Up for Lilly, CAT; J&J Posts Phase-3 Data
by Mark Vickery
With the GameStop (GME) short-squeeze saga continuing, market indexes work to regain their equilibrium.
Pharma Stock Roundup: JNJ, NVS Q4 Earnings, MRK & LLY's Coronavirus Updates
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) announce Q4 results. Merck (MRK), AbbVie (ABBV) & Pfizer (PFE) get EU approvals.
Will Glaxo (GSK) Q4 Earnings Recover From Coronavirus Woes?
by Zacks Equity Research
Glaxo's (GSK) new and specialty products are likely to have driven fourth-quarter sales. The results will provide clarity on the impact of coronavirus on the company's vaccine business.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $35.86, moving -1.05% from the previous trading session.
Markets Bounce Back; Visa (V) Beats, Mondelez (MDLZ) Meets
by Mark Vickery
The Dow, which reached +650 points at its intra-day high, closed up 300 points, or around 1%. The S&P 500 followed suit, finishing up +37 points.
Sanofi (SNY) to Manufacture BioNTech's Coronavirus Vaccine
by Zacks Equity Research
Sanofi (SNY) to support manufacturing and supply of BioNTech's COVID-19 vaccine candidate, which the latter has developed in partnership with Pfizer.
JNJ Touches New Highs Post Solid Q4 Earnings: ETFs in Focus
by Sweta Killa
The solid results coupled with upbeat vaccine data optimism pushed JNJ shares to all-time high.
Merck's (MRK) Keytruda Gets EC Nod for MSI-H Colorectal Cancer
by Zacks Equity Research
The European Commission approves Merck's (MRK) Keytruda as a monotherapy for first-line treatment of patients with metastatic MSI-H or dMMR colorectal cancer.
Pfizer (PFE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Pfizer's (PFE) key brands, Eliquis, Ibrance and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the fourth quarter.
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech and AstraZeneca
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $37.31, marking a +0.08% move from the previous day.
Earnings Preview: Pfizer (PFE) Q4 Earnings Expected to Decline
by Zacks Equity Research
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pfizer's (PFE) Bavencio Gets EU Nod for First-Line Bladder Cancer
by Zacks Equity Research
The European Commission approves Pfizer (PFE) and Merck KGaA's Bavencio as a monotherapy for first-line maintenance treatment in advanced/metastatic urothelial carcinoma.
How Long Will Coronavirus Vaccine Drive Moderna (MRNA) Stock?
by Zacks Equity Research
Moderna's (MRNA) progress with coronavirus vaccine development and its approval is driving its share prices for the past year. Will the trend continue?
Pfizer (PFE) to Supply 40M Doses of Coronavirus Vaccine to COVAX
by Zacks Equity Research
Pfizer (PFE) and BioNTech inks an agreement with COVAX to supply up to 40 million doses of their COVID-19 vaccine, BNT162b2.
Exelixis (EXEL) Wins FDA Nod for Cabometyx + Opdivo in RCC
by Zacks Equity Research
Exelixis (EXEL) obtains FDA approval for Cabometyx in combination with immuno-oncology drug, Opdivo, for the first-line treatment of patients with advanced kidney cancer.
The Zacks Analyst Blog Highlights: Amazon, JPMorgan, Pfizer, Salesforce and Chevron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amazon, JPMorgan, Pfizer, Salesforce and Chevron
VBI Vaccines (VBIV) Provides Updates on COVID-19 Vaccine
by Zacks Equity Research
VBI Vaccines (VBIV) plans to begin a phase I/II study of monovalent vaccine candidate, VBI-2902, in the first quarter of 2021.
Q4 Earnings Season Scorecard and Analyst Reports for Amazon, JPMorgan & Pfizer
by Sheraz Mian
Today's Research Daily features an update on the Q4 earnings season and new research reports on Amazon.com (AMZN), JPMorgan Chase (JPM), Pfizer (PFE) and others.
Moderna's (MRNA) Coronavirus Vaccine Study Begins in Japan
by Zacks Equity Research
Moderna's (MRNA) partner Takeda doses the first participant in a phase I/II study with Moderna's coronavirus vaccine candidate, mRNA-1273 in Japan.